江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 重要风险提示： 证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-091 江苏吴中医药发展股份有限公司（以下简称"公司"）股票连续三个交 易日内收盘价格涨幅偏离值累计超过 12%，属于股票交易异常波动的情形。公司 股票近期涨幅较大，经核实，公司不存在应披露未披露信息，可能存在市场情绪 过热及非理性炒作迹象，交易风险较大，存在下跌的风险。公司股票存在多重退 市风险，敬请广大投资者理性投资、审慎决策，切勿盲目跟风炒作，避免因公司 股价波动造成投资损失。 2025 年 7 月 13 日，公司收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《行政处罚事先告知书》（处罚字〔2025〕58 号），具体 内容详见公司于 2025 年 7 月 14 日披露的《关于收到中国证券监督管理委员会< 行政处罚事先告知书>的公告》（公告编号：临 2025-064）。公司股票已于 2025 年 7 月 14 日起被叠加实施退市风险警示，如根据中国证监会正式的处罚决定书 结论，公司触及重大违 ...

Core Insights - Small-cap stocks exhibit higher volatility and activity compared to large-cap stocks, making them potential market leaders [1] Market Overview - As of August 22, there are 947 stocks with a circulating market value below 3 billion yuan, and 392 stocks with a circulating market value below 2 billion yuan [1] - A total of 1,607 stocks have a total market value below 5 billion yuan, with 550 stocks below 3 billion yuan [1] Smallest Market Capitalization Stocks - The three stocks with the smallest circulating market values are: - *ST Zitian: 440 million yuan - Liren Technology: 601 million yuan - Bofei Electric: 632 million yuan [1] - The three stocks with the smallest total market values are: - *ST Zitian: 444 million yuan - *ST Suwu: 718 million yuan - *ST Yuancheng: 772 million yuan [1] Selected Stocks with Low Market Capitalization - A list of stocks with circulating market values below 2 billion yuan includes: - *ST Zitian: Circulating market value 440 million yuan, total market value 444 million yuan, P/E ratio 39.34, industry: Media - Liren Technology: Circulating market value 601 million yuan, total market value 2.018 billion yuan, P/E ratio 238.09, industry: Home Appliances - Bofei Electric: Circulating market value 632 million yuan, total market value 2.767 billion yuan, P/E ratio 161.11, industry: Basic Chemicals - Other notable stocks include: - Kuntai Co.: 652 million yuan circulating market value, 2.362 billion yuan total market value, P/E ratio 89.79, industry: Automotive - Hongming Co.: 662 million yuan circulating market value, 2.015 billion yuan total market value, P/E ratio 124.86, industry: Machinery [1][2]

Group 1 - The stock exchange has implemented monitoring measures for stocks that exhibit significant abnormal fluctuations in trading, particularly focusing on large buy or sell orders within a one-minute timeframe during continuous bidding phases [1] Group 2 - A list of stocks under abnormal fluctuation monitoring has been provided, including their monitoring start and end dates, as well as the dates when the fluctuations began. Notable stocks include 思泉新材, *ST苏吴, 赛诺医疗, 东芯股份, and 长城军工 [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要风险提示： ● 江苏吴中医药发展股份有限公司（以下简称"公司"）股票8月21日、8月22日连续2个交易日涨幅较 大，公司股票存在多重退市风险，可能存在市场情绪过热及非理性炒作迹象，交易风险较大，存在短期 下跌的风险。敬请广大投资者理性投资、审慎决策，切勿盲目跟风炒作，避免因公司股价波动造成投资 损失。 ● 2025年7月13日，公司收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《行政处罚事 先告知书》（处罚字〔2025〕58号），公司股票已于2025年7月14日起被叠加实施退市风险警示，如根 据中国证监会正式的处罚决定书结论，公司触及重大违法强制退市情形，公司股票将被终止上市。敬请 广大投资者关注后续公告并注意投资风险。 一、公司存在重大违法退市风险 三、叠加实施其他风险警示 公司2024年度财务报告内部控制被年审机构出具无法表示意见；浙江复基控股集团有限公司的其他关联 方企业存在非经营性占用公司资金的情形。上述事 ...

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces multiple delisting risks due to significant violations and financial issues, prompting a warning for investors to exercise caution in trading [2][3][4]. Group 1: Major Violation Delisting Risk - On July 13, 2025, the company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating potential major violations that could lead to forced delisting [3]. - The company's stock has been under delisting risk warning since July 14, 2025, due to the aforementioned notice [3]. Group 2: Financial Delisting Risk - The company's 2024 annual financial report received a disclaimer of opinion from the auditing firm, triggering financial delisting risk under the Shanghai Stock Exchange listing rules [4]. - The stock has been subjected to delisting risk warning due to this financial issue [4]. Group 3: Additional Risk Warnings - The company has been issued additional risk warnings due to internal control issues in the 2024 financial report and non-operational fund occupation by related parties [5]. - Specific details regarding these additional risks were disclosed in announcements made on May 6, 2025 [5]. Group 4: Other Operational Risks - On July 18, 2025, Regen Biotech Inc. sent a termination letter to the company's subsidiary, impacting the sales of AestheFill [6]. - The controlling shareholder's shares are fully pledged or under judicial restrictions, indicating further operational risks [6].

Core Viewpoint - The domestic medical beauty industry is undergoing significant changes, with major players experiencing a decline in performance due to market shifts and increased competition from new regenerative materials like collagen and "童颜针" (youthful needle) [4][7][14]. Group 1: Industry Performance - The three major companies in the medical beauty sector, including 华熙生物, 爱美客, and 昊海生科, reported substantial declines in revenue and net profit, with 爱美客's revenue dropping by 21.59% to 12.99 billion yuan and net profit decreasing by 29.57% to 7.89 billion yuan in the first half of 2024 [7][8]. - 爱美客's core products, including "嗨体" and "濡白天使," saw revenue declines of 23.79% and 23.99%, respectively, despite maintaining high gross margins of over 90% [6][7]. Group 2: Market Trends - The introduction of "童颜针," particularly the imported product 艾塑菲, has gained rapid popularity, with sales reaching 20,000 units and contributing over 800 million yuan in revenue within two months of its launch [5][17]. - The shift towards regenerative materials is evident, as "童颜针" offers longer-lasting effects and a different mechanism compared to traditional hyaluronic acid fillers, which are facing price declines due to increased competition [16][17]. Group 3: Strategic Moves - 爱美客's acquisition of REGEN, a Korean medical beauty company, for 1.386 billion yuan marks the largest cross-border acquisition in the domestic medical beauty industry, aiming to enhance its product portfolio and market presence [5][9]. - The ongoing dispute between 江苏吴中 and 爱美客 over the distribution rights of 艾塑菲 highlights the competitive landscape and the challenges of dependency on agency models in the medical beauty sector [19][20]. Group 4: R&D and Innovation - 爱美客 has increased its R&D investment to 1.57 billion yuan, representing 12.05% of its revenue, indicating a focus on enhancing its competitive edge through innovation [8]. - The company holds 182 valid patents, including 53 invention patents, showcasing its commitment to developing proprietary technologies [8].

Core Viewpoint - The company faces significant risks of delisting due to major violations and financial issues, as indicated by recent regulatory actions and financial report evaluations [1][2][3] Group 1: Delisting Risk - The company has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), which may lead to mandatory delisting if major violations are confirmed [1][3] - The company's stock has been under delisting risk warning since July 14, 2025, due to potential major violations [1][3] Group 2: Financial Reporting Issues - The company's 2024 financial report received a disclaimer of opinion from the auditing firm, triggering delisting risk warnings under the Shanghai Stock Exchange rules [1][2] - The company is also facing additional risk warnings due to internal control issues highlighted in the 2024 financial report [2] Group 3: Other Operational Risks - The company is involved in a legal arbitration case with a partner, which may affect its ability to continue sales of certain products [2] - There are indications of non-operational fund occupation by related parties, which has led to further risk warnings [2]

New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]

证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-090 江苏吴中医药发展股份有限公司 关于股票交易暨退市风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要风险提示： 二、公司存在财务类退市风险 公司 2024 年度财务报告被年审机构出具无法表示意见，触及《上海证券交 易所股票上市规则》第 9.3.2 条第（三）项规定财务类退市的情形，公司股票已 被上海证券交易所实施退市风险警示。具体内容详见公司于 2025 年 4 月 30 日披 露的《关于实施退市风险警示及叠加其他风险警示暨停牌的公告》（公告编号： 临 2025-032）。 三、叠加实施其他风险警示 公司 2024 年度财务报告内部控制被年审机构出具无法表示意见；浙江复基 控股集团有限公司的其他关联方企业存在非经营性占用公司资金的情形。上述事 项触及《上海证券交易所股票上市规则》第 9.8.1 条第（一）（三）项的规定， 公司被叠加实施其他风险警示。具体内容详见公司于 2025 年 5 月 6 日披露的《关 于控股股东关联方资金占用暨叠加 ...

Group 1 - The average stock price of A-shares is 13.27 yuan, with 33 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.01 yuan [1] - Among the low-priced stocks, 13 are ST stocks, accounting for 39.39% of the total [1] - The Shanghai Composite Index closed at 3825.76 points as of August 22 [1] Group 2 - The top gainers among low-priced stocks include *ST Suwu, Jinju Group, and *ST Xingguang, with increases of 5.21%, 1.82%, and 1.55% respectively [1] - The top decliners include *ST Gaohong, *ST Jinke, and Jiugang Hongxing, with decreases of 5.00%, 1.46%, and 1.14% respectively [1] - The trading volume and turnover rates vary significantly among low-priced stocks, with *ST Suwu having a turnover rate of 3.49% [1]